uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 12:10PM GMT
Release Date Price: $48.03
David Ryan Lewis
Morgan Stanley, Research Division - MD

Good morning. Before I get going, let me just read the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.

Now I'd like to welcome you all to our first session here in this room at the 2019 Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here, David Lewis. And I would like to welcome to the stage with me the CEO of uniQure, Matt Kapusta.

Matthew Craig Kapusta
uniQure N.V. - CEO, Interim CFO & Executive Director

Thank you.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

Now uniQure, of course, is a pioneer in the gene therapy space, first company ever to have a gene therapy actually approved

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot